Belozeroff V, Chertow GM, Graham CN, Dehmel D, Parfrey PS, Briggs AH. Economic evaluation of cinacalcet in the United States: the EVOLVE trial. Value Health. 2015 Dec;18(8):1079-87. doi: 10.1016/j.jval.2015.08.007
Basarir H, Brennan A, Jacques R, Pollard DJ, Stevens K, Freeman J. The cost-effectiveness of the Kids in Control OF Food (KICk-OFF) structured education programme for adolescents with type 1 diabetes. Presented at the 2015 British Society for Paediatric Endocrinology and Diabetes; November 27, 2015. Sheffield, United Kingdom.
Traina SB, McQuarrie K, Barrett A, DiBenedetti D, McLeod L. Content validity of the current health satisfaction questionnaire (CHES-Q) among people living with type 2 diabetes mellitus and comorbid chronic kidney disease (CKD). Poster presented at the 2015 ISPOR 18th Annual European Congress; November 2015. Milan, Italy.
Bachmann T, Vandenberghe F, Saigi-Morgui N, Delacretaz A, von Gunten A, Conus P, Eap C. Pharmacogenetic study on type 2 diabetes induced by psychotropic drugs. Poster presented at the Congress of the Swiss Association of Public Health Administration and Hospital Pharmacists; October 26, 2015. Zurich, Switzerland.
Basarir H, Brennan A, Jacques R, Pollard D, Stevens K, Freeman J, Wales J, Price K. The cost-effectiveness of the Kids in Control OF Food (KICk-OFF) structured education programme in a paediatric population with type 1 diabetes mellitus in the UK. Poster presented at the 2015 International Society for Pediatric and Adolescent Diabetes (ISPAD) and Australasian Paediatric Endocrine Group (APEG) Joint Conference; October 2015. Brisbane, Australia. [abstract] Pediatr Diabetes. 2015 Oct 6; 16(Suppl 21):85.
Kruger J, Pollard D, Basarir H, Thokala P, Cooke D, Clark M, Bond R, Heller S, Brennan A. Incorporating psychological predictors of treatment response into health economic simulation models: a case study in type 1 diabetes. Med Decis Making. 2015 Oct;35(7):872-87. doi: 10.1177/0272989X15590143
Wolowacz S, Pearson I, Shannon P, Chubb B, Gundgaard J, Davies M, Briggs A. Development and validation of a cost-utility model for Type 1 diabetes mellitus. Diabet Med. 2015 Aug;32(8):1023-35. doi: 10.1111/dme.12663
Andrews EB, Gilsenan AW, Midkiff KD, Harris DH. Comments on Bang et al.: the impact of recombinant parathyroid hormone on malignancies and mortality: 7 years of experience based on nationwide Danish registers. Osteoporos Int. 2015 May;26(5):1663-4. doi: 10.1007/s00198-014-3003-z
Brennan VK, Mauskopf JA, Colosia AD, Copley-Merriman K, Hass B, Palencia R. Utility estimates for patients with type 2 diabetes mellitus after experiencing a myocardial infarction or stroke: a systematic review. Expert Rev Pharmacoecon Outcomes Res. 2015 Feb;15(1):111-23.
Pladevall M, Divine G, Wells KE, Resnicow K, Williams LK. A randomized controlled trial to provide adherence information and motivational interviewing to improve diabetes and lipid control. Diabetes Educ. 2015 Feb;41(1):136-46.
Herring WL, Grant TJ, Mladsi DM. A mathematical model to estimate the health benefits and costs of diabetic retinopathy screening programs. Presented at the 2015 Institute for Operations Research and Management Science Computing Conference; January 12, 2015. Richmond, VA.
Doward L, Højbjerre L, Hogue S, Fernandez M, Barrett A, Crawford R, Kragh N, Aagren M. Influence of patient-reported outcomes on regulatory, HTA, and market access decisions: obesity and diabetes case examples. Poster presented at the 2015 ISPOR 20th Annual International Meeting; May 2015. Philadelphia, PA. [abstract] Value Health. 2015; 18:A1-A333.